RESUMEN

Lyme disease (LD) is the prototype of tick-borne infections. The broad spectrum of LD symptomatology, together with the tremendous variety of sensibility and specificity of diagnostic tests, poses a complex challenge for LD diagnosis. Here, we propose a clinical algorithm for Lyme patients to prevent treatment delay in suspicious scenarios.

Asunto(s)

RESUMEN

The field of data analysis, preparation, and machine learning is rapidly expanding, offering numerous libraries and resources for exploration. Researchers gain knowledge through various channels, but few resources provide a comprehensive framework for building machine-learning models. We present a step-by-step framework for constructing a robust Random Forest classification model to fill this gap. Using the trained model, we predict if individuals visiting Sanoviv Medical Institute between 2020 and 2023 participated in the Lyme disease program based on age, symptoms, blood count, and chemistry results. While not exhaustive, the methods in each step provide a valuable starting point for researchers, promoting an understanding of the fundamental approach to model creation. The framework encourages researchers to explore beyond the outlined techniques, fostering innovation and experimentation.

Asunto(s)

RESUMEN

Currently, there are over 602 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases and 6.4 million COVID-19 disease-related deaths worldwide. With ambitious vaccine strategies, reliable and accurate serological testing is needed to monitor the dynamics of the novel coronavirus pandemic and community immunity. We set out to improve serological testing of the immune response against SARS-CoV-2. We hypothesize that by multiplexing the serological diagnostic test kit (SARSPLEX) and screening for three antibodies, an even more robust diagnostic can be developed. A total of 293 sera were analyzed for IgM, IgG, or IgA immune reactions to the subunit 1 spike glycoprotein and the nucleocapsid protein in a standardized ELISA platform. Testing IgM, IgG, and IgA demonstrated high positive and negative agreements compared to RT-PCR and serology reference tests. Comparison with the pre-2019-CoV (n = 102) samples highlighted the specificity of this test kit and indicated that no unspecific binding, even with the summer flu patients (n = 44), was detected. In addition, SARSPLEX demonstrated to be a valuable occupational surveillance tool used in a functional medicine facility. With increased and broader testing, SARSPLEX will be a valuable tool in monitoring immunity and aid in prioritizing access to the SARS-CoV-2 vaccine for high-risk patients.

Asunto(s)

RESUMEN

OBJECTIVE: To identify the cancer incidence and mortality in Mexican Social Security Institute beneficiary (MSSI-B) children during 1996-2013. MATERIALS AND METHODS: Both cancer cases (n=4 728) and deaths (n=2 378) were analyzed in MSSI-B children who were registered in five states of the Mexican Republic. The incidence and mortality trends and the incidences (rate x 1 000 000 children / year) of the type of cancer, age, sex, and place of residence were obtained. RESULTS: For both indicators (incidence and mortality), there was a downward trend for the period of 1996-2001 and a stable trend for 2002-2013. This occurred in the overall mortality and incidence trends of the Estado de México and Chiapas and in the leukemia and the acute lymphoid subgroups. The annual overall incidence was 128 cases per 1 000 000 children. Leukemia, lymphomas, and central nervous system tumors were the principal cancer groups. CONCLUSIONS: Cancer mortality for the period of 2002-2013 did not diminish. Interinstitutional and/or international research should be designed to improve the care of these children.

Asunto(s)

RESUMEN

Abstract Objective: To identify the cancer incidence and mortality in Mexican Social Security Institute beneficiary (MSSI-B) children during 1996-2013. Materials and methods: Both cancer cases (n=4 728) and deaths (n=2 378) were analyzed in MSSI-B children who were registered in five states of the Mexican Republic. The incidence and mortality trends and the incidences (rate x 1 000 000 children / year) of the type of cancer, age, sex, and place of residence were obtained. Results: For both indicators (incidence and mortality), there was a downward trend for the period of 1996-2001 and a stable trend for 2002-2013. This occurred in the overall mortality and incidence trends of the Estado de México and Chiapas and in the leukemia and the acute lymphoid subgroups. The annual overall incidence was 128 cases per 1 000 000 children. Leukemia, lymphomas, and central nervous system tumors were the principal cancer groups. Conclusions: Cancer mortality for the period of 2002-2013 did not diminish. Interinstitutional and/or international research should be designed to improve the care of these children.

Resumen Objetivo: Mostrar la incidencia y mortalidad por cáncer en niños derechohabientes del Instituto Mexicano del Seguro Social (DH-IMSS) (periodo 1996-2013). Material y métodos: Se analizaron los casos (n=4 728) y las muertes (n=2 378) por cáncer en niños DH-IMSS registrados en cinco estados de la República mexicana. Se obtuvo la tendencia de la incidencia y mortalidad y la incidencia por tipo de cáncer, edad, sexo y lugar de residencia. Resultados: Para ambos indicadores (incidencia y mortalidad) hubo tendencia a la disminución para el periodo 1996-2001 y estabilidad para 2002-2013; esto sucedió para la tendencia global, para el Estado de México y Chiapas, para las leucemias y para el subgrupo de las linfoide agudas. La incidencia global fue de 128 x 1 000 000 niños/año; las leucemias, tumores del sistema nervioso central y linfomas fueron los principales grupos de cáncer. Conclusiones: La mortalidad por cáncer para el periodo 2002-2013 no ha disminuido; deben diseñarse investigaciones interinstitucionales e internacionales para mejorar la atención médica de estos niños.

Asunto(s)

RESUMEN

El objetivo de este estudio fue analizar el consumo de preparados a base de plantas medicinales entre los usuarios de los centros de salud de Atención Primaria de la ciudad de Barcelona. Es un estudio descriptivo transversal mediante encuesta telefónica a 400 usuarios atendidos en dichos centros. Los resultados muestran un consumo de plantas medicinales en un 59,3% de los participantes. Entre los consumidores, un 41,2% lo hace con una frecuencia diaria o semanal. Un 86,4% no comunican dicho consumo al personal sanitario. Dado el porcentaje de usuarios de la sanidad pública que usan preparados a base de plantas medicinales es importante registrarlo en la historia clínica, ya que estas son una herramienta terapéutica que puede servir para tratar ciertas patologías y también como complemento de otros tratamientos (AU)

O objetivo deste estudo foi analisar o uso de preparações à base de plantas medicinais por utentes de centros públicos de saúde da cidade de Barcelona. É um estudo descritivo transversal, efectuado mediante inquérito telefónico a 400 utentes atendidos nesses centros. Os resultados mostram um consumo de plantas medicinais de 59,3%. Entre os consumidores, 41,2% fazem-no com uma frequência diária ou semanal. 86,4% dos utentes não comunicam este uso aos profissionais de saúde. Atendendo à percentagem de utentes que utilizam as preparações à base de plantas medicinais é importante registá-lo na história clínica, já que estas são uma ferramenta terapêutica que nos pode ajudar a tratar certas doenças e também como um complemento de outros tratamentos

The objective of this study was to analyse the consumption of medicinal plant products by the users of the primary health care system in the city of Barcelona. It is a descriptive and transversal study carried out through a telephonic survey, in which 400 users of primary health-care public centres were interviewed. Results show that 59.3% of the participants were consumers of medicinal plants. Among the consumers, 41.2% took them in a daily or weekly basis and 86.4% did not communicate this consumption to health-care providers. Given the percentage of public health system users consuming medicinal plant products, it is important to register it in their medical record, since medicinal plants are a therapeutic tool that can be used for treating certain pathologies or as adjuvant in other treatments (AU)

Asunto(s)